Stock RNAZ TRANSCODE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
1.41 USD +6.02% Intraday chart for TransCode Therapeutics, Inc. +71.95% -78.61%
04-22 Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI
04-22 Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 32.73 8.733 4.136 8.612 - -
Enterprise Value (EV) 1 32.73 8.733 4.136 8.612 8.612 8.612
P/E ratio - - - - - -
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - - - - -
EV / FCF - -550,536 x - - - -
FCF Yield - -0% - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 16.1 16.2 627 6,108 - -
Reference price 2 2,032 538.4 6.592 1.410 1.410 1.410
Announcement Date 31/03/22 31/03/23 01/04/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - -
EBITDA - - - - - -
EBIT 1 -6.151 -18.67 -19.42 -14.7 -22.1 -33.1
Operating Margin - - - - - -
Earnings before Tax (EBT) - - - - - -
Net income - - - - - -
Net margin - - - - - -
EPS - - - - - -
Free Cash Flow - -15.86 - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 31/03/22 31/03/23 01/04/24 - - -
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - -
EBITDA - - - - - - - - - - - -
EBIT 1 -2.986 -4.707 -4.954 -5.527 - -5.131 -5.328 -4.059 -3.2 -3.4 -3.8 -4.3
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - -
Net income - - - - -4.817 - - - - - - -
Net margin - - - - - - - - - - - -
EPS - - - - -264.0 - - - - - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 31/03/22 15/08/22 14/11/22 31/03/23 15/05/23 14/08/23 14/11/23 01/04/24 - - - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -15.9 - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex - 0.1 - - - -
Capex / Sales - - - - - -
Announcement Date 31/03/22 31/03/23 01/04/24 - - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.41 USD
Average target price
3 USD
Spread / Average Target
+112.77%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
TRANSCODE THERAPEUTICS, INC. Stock TransCode Therapeutics, Inc.
-78.61% 8.61M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
+1.28% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RNAZ Stock
  4. Financials TransCode Therapeutics, Inc.